Key result
Combination chemotherapy for osteogenic sarcoma was associated with an unusual neurological syndrome of abrupt focal cerebral deficits in 4 of 158 patients (2.5%).
Population
158 patients treated for osteogenic sarcoma
Design
Case_series
Authors
Loading...
Warrants monitoring for focal deficits during osteogenic sarcoma chemotherapy; leaves open causality and incidence.
Observational (n=158)
Combination chemotherapy with vincristine and high-dose methotrexate for osteogenic sarcoma may be associated with a transient neurological syndrome characterized by focal cerebral deficits.
Allen et al. (1978) conducted an observational in Osteogenic sarcoma (n=158). Combination chemotherapy (vincristine, high-dose methotrexate, citrovorum factor rescue) was evaluated on Unusual neurological syndrome (focal cerebral deficits). Combination chemotherapy for osteogenic sarcoma was associated with an unusual neurological syndrome of abrupt focal cerebral deficits in 4 of 158 patients (2.5%).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: